Chelmsford, MA, United States of America

Rayomand H Gimi

This inventor holds 14 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Genzyme Corporation, F-Star Therapeutics, Inc., Invox Pharma Limited. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rayomand H Gimi. Retrieved from https://idiyas.com/inventor/rayomand-h-gimi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Bridgewater, NJ (US) (2017 - 2021)
Chelmsford, MA (US) (2004 - 2023)

Company Filing History:

F-Star Therapeutics, Inc.

Sperovie Biosciences, Inc.

patents

Years Active: 2004-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667573 - Compounds, compositions, and methods for the treatment of disease (2026-06-30),

2. 12187761 - Compounds, compositions, and methods for the treatment of disease (2025-01-07),

3. 11744845 - Compounds,compositions, and methods for the treatment of disease (2023-09-05),

4. 11584774 - Compounds, compositions, and methods for the treatment of disease (2023-02-21),

5. 11033569 - Compounds,Compositions, and methods for the treatment of disease (2021-06-15),

6. 10954230 - Method of preparing glucosylceramide synthase inhibitors (2021-03-23),

7. 10604518 - Method of preparing glucosylceramide synthase inhibitors (2020-03-31),

8. 10065949 - Method of preparing glucosylceramide synthase inhibitors (2018-09-04),

9. 9682975 - Method of preparing glucosylceramide synthase inhibitors (2017-06-20),

10. 7285670 - Synthesis of substituted thiazoline carboxylic acids (2007-10-23),

11. 7115769 - Synthesis of 2-alkylcysteine via phase transfer catalysis (2006-10-03),

12. 6982335 - Synthesis of substituted thiazoline carboxylic acids (2006-01-03),

13. 6878828 - Synthesis of 2-alkylcysteine via substituted thiazoline ester (2005-04-12),

14. 6794515 - Synthesis of 2-alkylcysteine via substituted thiazoline amide (2004-09-21),

Title: The Innovations of Rayomand H. Gimi

Introduction

Rayomand H. Gimi, located in Chelmsford, MA, is a distinguished inventor with a remarkable portfolio comprising 13 patents. His work primarily focuses on the development of compounds and compositions that activate pattern recognition receptors, contributing significantly to the field of medical treatments.

Latest Patents

Among his latest innovations are two notable patents titled "Compounds, compositions, and methods for the treatment of disease." These patents disclose compounds and compositions designed for the activation or induction of expression of critical pattern recognition receptors, including STING, RIG-I, and MDA5, highlighting innovative methods for their utilization in medical therapies.

Career Highlights

Throughout his career, Rayomand Gimi has made significant contributions while working with prominent organizations, including Genzyme Corporation and F-star Therapeutics, Inc. His expertise and innovative approaches in the biomedical field have led to advancements in therapies that target various diseases.

Collaborations

In his professional journey, Rayomand has collaborated with notable individuals in the industry, including Mukund Shankar Chorghade and Craig S. Siegel. These collaborations have undoubtedly enriched his work and broadened the impact of his inventions.

Conclusion

Rayomand H. Gimi's contributions to the field of medicine through his inventive compounds and methods are commendable. With his extensive patent portfolio and collaborative efforts, he continues to pave the way for innovations that could transform treatment options for various diseases. His work exemplifies the spirit of invention and the relentless pursuit of advancements that benefit society.

Profile summary based on public USPTO records.